MedPath

KYV-101 Receives FDA Fast Track Designation for Stiff Person Syndrome Treatment

• Kyverna Therapeutics' KYV-101, a CAR-T cell therapy, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for stiff person syndrome. • The RMAT designation will facilitate closer collaboration with the FDA to accelerate the development, review, and potential approval of KYV-101. • The FDA's decision was based on promising early clinical trial results, indicating KYV-101's potential to address the unmet needs in treating stiff person syndrome. • KYV-101 aims to "reset" the immune system in autoimmune diseases and is currently in Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis.

Kyverna Therapeutics' KYV-101, a CAR-T cell therapy, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of stiff person syndrome, a rare and debilitating neurological disorder. This designation is intended to expedite the development and review process for promising therapies addressing serious or life-threatening conditions with unmet medical needs.
The FDA's decision to grant RMAT designation to KYV-101 was based on preliminary clinical evidence suggesting the drug's potential to address the significant unmet needs in stiff person syndrome. The RMAT designation allows Kyverna Therapeutics to work more closely with the FDA, potentially accelerating the path to market for this novel therapy.

Clinical Significance and Mechanism of Action

Stiff person syndrome is a rare autoimmune neurological disorder affecting approximately one or two people per million. The condition is characterized by muscle rigidity, pain, spasms, and impaired mobility, significantly impacting patients' quality of life. Current treatments offer limited relief, highlighting the urgent need for more effective therapies.
KYV-101 is a CAR-T cell therapy designed to "reset" the immune system in patients with autoimmune diseases. The therapy involves modifying a patient's T cells to target and eliminate the autoreactive immune cells that contribute to the pathogenesis of stiff person syndrome. This approach aims to provide long-lasting remission by addressing the underlying cause of the disease.

Ongoing Clinical Trials and Future Directions

KYV-101 has been administered to 50 patients with oncological and autoimmune conditions across multiple sites in Europe and the U.S. Kyverna Therapeutics is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of KYV-101 in patients with stiff person syndrome, multiple sclerosis, and myasthenia gravis. Phase 1 and 2 trials are also underway for systemic sclerosis and lupus.
According to Peter Maag, PhD, CEO of Kyverna, the RMAT designation underscores the scientific community's recognition that fast-tracking this treatment could potentially save lives. The company is committed to supporting patients and addressing their unmet clinical needs by conducting patient-centric clinical trials to provide access to the latest advancements in CAR-T therapy for autoimmune diseases.
Dr. Amanda Piquet, director of the Autoimmune Neurology Program at CU Anschutz Medical Campus, who is not involved in the development of KYV-101, expressed optimism about the potential impact of the KYSA-8 trial on the treatment landscape for stiff person syndrome. She emphasized the devastating effects of the disease and the need for innovative therapies that can significantly improve patient outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves New Vial Sizes of Niktimvo for Chronic Graft-Versus-Host Disease

The FDA has approved Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for chronic graft-versus-host disease (GVHD) after two prior systemic therapies.
Niktimvo is the first FDA-approved treatment targeting CSF-1R to reduce inflammation and fibrosis in chronic GVHD, offering a novel approach for patients.

Spinogenix's SPG601 Shows Promise in Phase 2 Trial for Fragile X Syndrome

Spinogenix's SPG601 demonstrated a significant reduction in high-frequency gamma band activity, an EEG abnormality associated with Fragile X syndrome (FXS).
The Phase 2 trial met its primary endpoint, suggesting SPG601's potential to improve brain activity related to learning and memory in FXS patients.

uniQure Receives FDA Nod for Accelerated Approval Pathway for Huntington's Disease Gene Therapy

uniQure secured FDA agreement to pursue accelerated approval for its Huntington's disease gene therapy, potentially expediting treatment availability.
The FDA's decision reflects a more flexible approach to genetic medicines for severe rare diseases under Peter Marks.

KYV-101 Receives Orphan Drug Status in Europe for Myasthenia Gravis

KYV-101, an experimental cell therapy, has been granted orphan drug status by the European Medicines Agency for the treatment of myasthenia gravis (MG).
This designation offers benefits such as trial protocol assistance, reduced regulatory fees, and a 10-year market exclusivity period upon approval in Europe.

FDA Approves Syndax's Revuforj, a First-in-Class Menin Inhibitor for Acute Leukemia

The FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for adults and children with relapsed or refractory acute leukemia with KMT2A rearrangement.
Revuforj, a menin inhibitor, showed a complete remission or complete remission with partial hematologic recovery in 21.2% of study participants, with a median response duration of 6.4 months.

Abata Therapeutics' ABA-101 Treg Therapy Receives FDA Fast Track Designation for Progressive Multiple Sclerosis

Abata Therapeutics' ABA-101, an autologous regulatory T-cell (Treg) therapy, has been granted Fast Track designation by the FDA for progressive multiple sclerosis (MS).
ABA-101 has demonstrated a tolerable safety profile and therapeutic effect in animal models, showing antigen-dependent Treg functionality and anti-inflammatory cytokine production.

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel

Adaptimmune Therapeutics plc has announced the U.S. FDA's acceptance for priority review of its Biologics License Application for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma, marking a significant step towards offering a new treatment option for this condition.

FDA Approves Santhera's Agamree (Vamorolone) for Duchenne Muscular Dystrophy

The FDA has approved Agamree (vamorolone) for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, offering a novel corticosteroid treatment option.
Agamree demonstrated comparable efficacy to standard corticosteroids in clinical trials, with data suggesting a reduction in adverse events related to bone health, growth, and behavior.

FDA Grants Breakthrough Therapy Designation for Affinity Enhanced T-Cell Therapy in Synovial Sarcoma

The FDA has granted Breakthrough Therapy designation to Adaptimmune Therapeutics plc for its affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma, highlighting the therapy's potential in treating this form of cancer. The designation is based on promising results from a phase I/II trial, showing significant response rates among patients.

FDA Grants Breakthrough Therapy Designation to Adaptimmune's T-Cell Therapy for Synovial Sarcoma

The FDA granted Breakthrough Therapy designation to Adaptimmune's affinity-enhanced T-cell therapy targeting NY-ESO for synovial sarcoma, expediting its development.
The designation was based on Phase I/II trial results showing a 60% response rate in patients receiving the target dose of engineered T-cells.

Reference News

[1]
New drug for stiff person syndrome granted fast-track designation from FDA | Fox News
foxnews.com · Jul 15, 2024

Kyverna Therapeutics' KYV-101, a new CAR-T cell therapy for stiff person syndrome, received FDA's RMAT designation, prom...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy